Consensus PTC Therapeutics, Inc.

Stocks

PTCT

US69366J2006

Pharmaceuticals

Market Closed - Nasdaq 01:00:00 12/11/2026 +04			5-day change	1st Jan Change
64.91 ^USD	+1.20%		-4.71%	-14.55%

11-03	PTC Therapeutics Approves $500 Million Share Repurchase Program	MT
11-03	PTC Therapeutics, Inc. authorizes a Buyback Plan.	CI

Evolution of the Average Target: PTC Therapeutics, Inc.

Evolution of the Target Price: PTC Therapeutics, Inc.

Changes in Analyst Recommendations: PTC Therapeutics, Inc.

1454d7ccaa2ea2e06.cA-cbhQuAZci2rGE4OCWIZGEcaY_q_TQ1mE6Rxs9G98.RUuvFF9cLMd1kIfLhq_AEeOzPdAJmI7ouDdScXoEae46QtUoLWVnyFWx8A~da9947d57673b7555b676237babc9ef9

Analysts' recommendations: PTC Therapeutics, Inc.

10-30	PTC Therapeutics' Sephience Drug to Grow at Steady Pace With International Expansion, RBC Says	MT
10-30	RBC Raises Price Target on PTC Therapeutics to $77 From $75, Keeps Sector Perform Rating	MT
10-15	UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating	MT
10-08	RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating	MT
10-07	PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says	MT
07-27	PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says	MT
07-07	RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating	MT
06-09	PTC Therapeutics Shares Rise After Upgrade From Citigroup	MT
06-09	Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76	MT
05-08	TD Cowen Upgrades PTC Therapeutics to Buy From Hold, Adjusts Price Target to $90 From $75	MT
04-07	RBC Adjusts Price Target on PTC Therapeutics to $81 From $82, Maintains Sector Perform Rating	MT
02-23	Morgan Stanley Lifts Price Target on PTC Therapeutics to $92 From $90, Keeps Overweight Rating	MT
02-20	RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating	MT
01-08	RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating	MT
12-02	PTC Therapeutics Shares Drop After RBC Downgrade	MT
12-01	RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82	MT
11-05	RBC Capital Adjusts PTC Therapeutics Price Target to $82 From $70, Maintains Outperform Rating	MT
08/10/25	RBC Raises Price Target on PTC Therapeutics to $70 From $63, Keeps Outperform Rating	MT
08/08/25	RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating	MT
08/08/25	Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating	MT
29/07/25	UBS Adjusts Price Target on PTC Therapeutics to $80 From $71, Maintains Buy Rating	MT
29/07/25	Truist Raises Price Target on PTC Therapeutics to $86 From $80, Keeps Buy Rating	MT
04/06/25	RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating	MT
09/05/25	BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55	MT
07/05/25	Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PTC THERAPEUTICS, INC.					+56.64%
	ELI LILLY AND COMPANY					+1.47%
	JOHNSON & JOHNSON					-0.49%
	ABBVIE INC.					+5.7%
	ROCHE HOLDING AG					-1.34%
	MERCK & CO., INC.					+9.1%
	NOVARTIS AG					-5.5%
	ASTRAZENECA PLC					+16.05%
	AMGEN INC.					-7.63%
	GILEAD SCIENCES, INC.					+2.28%
	Average					+7.63%
	Weighted average by Cap.					+2.12%